U.S. markets close in 3 hours 8 minutes

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
243.96-2.96 (-1.20%)
As of 12:51PM EST. Market open.

Biogen Inc.

225 Binney Street
Cambridge, MA 02142
United States
617 679 2000
http://www.biogen.com

Sector(s)Healthcare
IndustryDrug Manufacturers—General
Full Time Employees7,400

Key Executives

NameTitlePayExercisedYear Born
Mr. Michel VounatsosCEO & Director5.72MN/A1962
Ms. Susan H. AlexanderExec. VP, Chief Legal Officer & Sec.1.99M1.77M1957
Dr. Alfred W. Sandrock Jr.Exec. VP of R&D1.87MN/A1958
Mr. Chirfi GuindoExec. VP of Global Product Strategy & Commercialization1.32MN/A1966
Mr. Michael R. McDonnellExec. VP & CFON/AN/A1964
Ms. Robin C. KramerVP & Chief Accounting OfficerN/AN/A1966
Mr. Mark J. HernonSr. VP & Chief Information OfficerN/AN/A1964
Mr. Joe MaraVP of Fin. & Head of Investor RelationsN/AN/AN/A
Ms. Natacha GassenbachChief Communication Officer & Head of Corp. AffairsN/AN/AN/A
Dr. Ginger GregoryExec. VP & Chief HR OfficerN/AN/A1968
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaborations with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Co., Ltd.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; Sangamo Therapeutics Inc.; ISD Immunotech; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Biogen Inc.’s ISS Governance QualityScore as of November 2, 2019 is 4. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 2; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.